VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH MM 2018 | CAR T-cells for multiple myeloma: update & what’s in store for ASH 2018

CAR T-cells have gone from strength to strength in the field of hem-onc, and it looks like the next malignancy they are set to revolutionize treatment for is multiple myeloma (MM). We spoke to Jesús Berdeja, MD, of the Sarah Cannon Center for Blood Cancer, Nashville, TN, to find out more. Dr Berdeja discusses the current landscape for CAR T-cells in MM, with multiple agents currently in trials for which updates are expected at ASH 2018, including bb2121. This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter